163 related articles for article (PubMed ID: 32271432)
1. USP3 promotes proliferation of non-small cell lung cancer through regulating RBM4.
Liao XH; Wang Y; Zhong B; Zhu SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3143-3151. PubMed ID: 32271432
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-597 inhibits NSCLC progression through negatively regulating CDK2 expression.
Yu DJ; Li YH; Zhong M
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4288-4297. PubMed ID: 32373965
[TBL] [Abstract][Full Text] [Related]
3. LncRNA TRERNA1 promotes malignant progression of NSCLC through targeting FOXL1.
Luo DB; Lv HB; Sun XH; Wang Y; Chu JH; Salai AL
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1233-1242. PubMed ID: 32096153
[TBL] [Abstract][Full Text] [Related]
4. LncRNA HOXA-AS2 regulates microRNA-216a-5p to promote malignant progression of non-small cell lung cancer.
Cui TJ; Lin GS; Dai YM; Zheng JP; Chen Z; Chen Q; Zheng Y; Lin X
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):264-273. PubMed ID: 31389597
[TBL] [Abstract][Full Text] [Related]
5. USP3 promotes cisplatin resistance in non-small cell lung cancer cells by suppressing ACOT7-regulated ferroptosis.
Tao R; Liu Z; Zhang Z; Zhang Z
Anticancer Drugs; 2024 Jul; 35(6):483-491. PubMed ID: 38502867
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-424-5p inhibits the development of non-small cell LCa by binding to ITGB1.
Xu ZL; Zhang M; Chen SX; Qiu M; Zhang Q; Gao LP; Li JDX
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8921-8930. PubMed ID: 31696479
[TBL] [Abstract][Full Text] [Related]
7. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
8. LncRNA WT-AS inhibits metastatic ability of non-small cell lung cancer by regulating KLK13.
Wang Y; Tan TZ; Wang LQ; Zhang K
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9429-9437. PubMed ID: 33015785
[TBL] [Abstract][Full Text] [Related]
9. MAGI1-IT1 stimulates proliferation in non-small cell lung cancer by upregulating AKT1 as a ceRNA.
Zhang G; Chen HX; Yang SN; Zhao J
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):691-698. PubMed ID: 32016970
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of LncRNA FOXC2-AC1 promoting lung cancer metastasis by regulating miR-107.
Wu XF; Lu JT; Chen W; Wang N; Meng JC; Zhou YH
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):690-698. PubMed ID: 30720176
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion.
Li Q; Ran P; Zhang X; Guo X; Yuan Y; Dong T; Zhu B; Zheng S; Xiao C
Cell Physiol Biochem; 2018; 50(3):987-1004. PubMed ID: 30355927
[TBL] [Abstract][Full Text] [Related]
12. LncRNA BX357664 inhibits the proliferation and invasion of non-small cell lung cancer cells.
Yang J; Du YM; Li B
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):660-669. PubMed ID: 30720174
[TBL] [Abstract][Full Text] [Related]
13. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621.
Chen ZY; Liu HY; Jiang N; Yuan JM
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9939-9946. PubMed ID: 31799663
[TBL] [Abstract][Full Text] [Related]
14. MiRNA-621 inhibits the malignant progression of non-small cell lung cancer via targeting SIX4.
Zhang M; Shi H; Zhang C; Zhang SQ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4807-4814. PubMed ID: 31210312
[TBL] [Abstract][Full Text] [Related]
15. CLK2 promotes occurrence and development of non-small cell lung cancer.
Liu B; Kong X; Wang R; Xin C
J BUON; 2021; 26(1):58-64. PubMed ID: 33721432
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-19a promotes proliferative and migratory abilities of NSCLC cells by inhibiting PTEN expression.
Shi J; Han Y; Lin D; Wang K; Liu B; Gao C
J BUON; 2019; 24(3):955-962. PubMed ID: 31424647
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-146-5p Promotes Pulmonary Artery Endothelial Cell Proliferation under Hypoxic Conditions through Regulating USP3.
Zhang W; Qi Y; Wu B
Dis Markers; 2021; 2021():3668422. PubMed ID: 34917199
[TBL] [Abstract][Full Text] [Related]
18. LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1.
Zhu FY; Zhang SR; Wang LH; Wu WD; Zhao H
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8377-8390. PubMed ID: 31646568
[TBL] [Abstract][Full Text] [Related]
19. LncRNA HANR aggravates the progression of non-small cell lung cancer via mediating miRNA-140-5p.
Li SJ; Wu YX; Liang YH; Gao Y; Wu AB; Zheng HY; Yang ZX
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):704-711. PubMed ID: 32016972
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of lncRNA FEZF1-AS1 in promoting the occurrence and development of oral squamous cell carcinoma through targeting miR-196a.
Xu L; Hou TJ; Yang P
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6505-6515. PubMed ID: 31378890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
